Volume : 10, Issue : 11, November – 2023
Title:
EXPLORING URINARY TRACT INFECTION: ADVANCEMENT IN UNDERSTANDING & TREATMENT
Authors :
Aniket P. Sawsakade*, Mr. Vivek D. Rathod, Dhiraj thadani, Pallavi Atalkar, Dipti Damodar, Sejal sahu, Shreyash padmawar
Abstract :
UTIs, which can occur in both community and clinical settings, are among the most prevalent bacterial illnesses in the world. Although there are many different types of UTIs, from simple (uUTIs) to complicated (cUTIs), the majority of UTIs are often treated empirically. Although fungi and some viruses have also been implicated in the development of UTIs, bacteria are the most common causal agents of these infections. The most frequent cause of both uUTIs and cUTIs is uropathogenic Escherichia coli (UPEC), which is followed in frequency by other pathogenic microbes such Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus spp. Furthermore, the prevalence of UTIs brought on by multidrug resistance (MDR) is rising, which has significantly accelerated the spread of antibiotic resistance. as well as the financial cost of these infections. Here, we go over the numerous causes of UTIs, including the pathogenicity of the bacteria that cause them and the development of infections with increasing resistance.
Keyword: UTIs, Virulence factor, Pathogenesis, Immune response, Advanced natural therapeutics.
Cite This Article:
Please cite this article in press Aniket P. Sawsakade et al, Exploring Urinary Tract Infection: Advancement In Understanding & Treatment., Indo Am. J. P. Sci, 2023; 10 (11).
Number of Downloads : 10
References:
1. Stamm, W.E.; Norrby, (2001) S.R. Urinary tract infections: Disease panorama and challenges. J. Infect. Dis. 183 (Suppl. S1), S1–S4.
2. Flores-Mireles, A.L.; Walker, J.N.; Caparon, M.; Hultgren, S.J. Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 2015, 13, 269–284.
3. McLellan, L.K.; Hunstad, D.A. Urinary Tract Infection: Pathogenesis and Outlook. Trends Mol. Med. 2016, 22, 946–957.
4. Lewis, A.J.; Richards, A.C.; Mulvey, M.A. Invasion of Host Cells and Tissues by Uropathogenic Bacteria. Microbiol. Spectr. 2016, 4, 359–381.
5. Storme, O.; Tiran Saucedo, J.; Garcia-Mora, A.; Dehesa-Davila, M.; Naber, K.G. Risk factors and predisposing conditions for urinary tract infection. Ther. Adv. Urol. 2019, 11, 1756287218814382.
6. Abraham, S.N.; Miao, Y. The nature of immune responses to urinary tract infections. Nat. Rev. Immunol. 2015, 15, 655–663.
7. Li, L.; Li, Y.; Yang, J.; Xie, X.; Chen, H. The immune responses to different Uropathogens call individual interventions for bladder infection. Front. Immunol. 2022, 13, 953354.
8. Grist M, Chakraborty J. Identification of a mucin layer in the urinary bladder. Urology. 1994;44:26–33.
9. Govindarajan, D.K.; Kandaswamy, K. Virulence factors of uropathogens and their role in host pathogen interactions. Cell Surf. 2022, 8, 100075.
10. Shrestha, L.B.; Baral, R.; Khanal, B. Comparative study of antimicrobial resistance and biofilm formation among Gram-positive uropathogens isolated from community-acquired urinary tract infections and catheter-associated urinary tract infections. Infect. Drug Resist. 2019, 12, 957–963.
11. Schmiemann, G.; Kniehl, E.; Gebhardt, K.; Matejczyk, M.M.; Hummers-Pradier, E. The diagnosis of urinary tract infection: A systematic review. Dtsch. Arztebl. Int. 2010, 107, 361–367.
12. Little, P.; Turner, S.; Rumsby, K.; Warner, G.; Moore, M.; Lowes, J.A.; Smith, H.; Hawke, C.; Mullee, M. Developing clinical rules to predict urinary tract infection in primary care settings: Sensitivity and specificity of near patient tests (dipsticks) and clinical scores. Br. J. Gen. Pract. J. R. Coll. Gen. Pract. 2006, 56, 606–612.
13. Ipe, D.S.; Horton, E.; Ulett, G.C. The Basics of Bacteriuria: Strategies of Microbes for Persistence in Urine. Front. Cell. Infect. Microbiol. 2016, 6, 14.
14. Kline, K.A.; Lewis, A.L. Gram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary Tract. Microbiol. Spectr. 2016, 4, 459–502.
15. Xu, R.; Deebel, N.; Casals, R.; Dutta, R.; Mirzazadeh, M. A New Gold Rush: A Review of Current and Developing Diagnostic Tools for Urinary Tract Infections. Diagnostics 2021, 11, 479.
16. Bedenic, B.; Mestrovic, T. Mechanisms of Resistance in Gram-Negative Urinary Pathogens: From Country-Specific Molecular Insights to Global Clinical Relevance. Diagnostics 2021, 11, 800.
17. van Buul, L.W.; Vreeken, H.L.; Bradley, S.F.; Crnich, C.J.; Drinka, P.J.; Geerlings, S.E.; Jump, R.L.P.; Mody, L.; Mylotte, J.J.; Loeb, M.; et al. The Development of a Decision Tool for the Empiric
18. Sims, M.; Mariyanovski, V.; McLeroth, P.; Akers, W.; Lee, Y.C.; Brown, M.L.; Du, J.; Pedley, A.; Kartsonis, N.A.; Paschke, A. Prospective, randomized, double-blind, Phase 2 doseranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J. Antimicrob. Chemother. 2017, 72, 2616–2626.
19. Kang, K.T.; Ng, K.; Kendrick, J.; Tilley, P.; Ting, J.; Rassekh, S.; Murthy, S.; Roberts, A. Thirdgeneration cephalosporin-resistant urinary tract infections in children presenting to the paediatric emergency department. Paediatr. Child Health 2020, 25, 166–172.
20. 3. Reid G. Potential preventive strategies and therapies in urinary tract infection. World J Urol. 1999;17(6):359–363.
21. Head KA. Natural approaches to prevention and treatment of infections of the lower urinary tract. Altern Med Rev. 2008;13(3):227–244.
22. Gur S, Turgut-Balik D, Gur N. Antimicrobial activities and some fatty acids of turmeric, ginger root and linseed used in the treatment of infectious diseases. World J Agricultural Sci. 2006;2:439–442.
23. Ahmad I, Aqil F. In vitro efficacy of bioactive extracts of 15 medicinal plants against ESβL-producing multidrug-resistant enteric bacteria. Microbiol Res. 2007;162:264–275.
24. Yarnell E. Botanical medicines for the urinary tract. World J Urol. 2002;20(5):285– 293.
25. Sahib AS, Mohammed IH, Hamdan SJ. Use of aqueous extract of corn silk in the treatment of urinary tract infection. J Intercult Ethnopharmacol. 2012;1(2):93– 96.
26. Pattanayak S, Das DC, Sinha NK, Parida S. Use of medicinal plants for the treatment of urinary tract infections: a study from Paschim Medinipur district, West Bengal, India. Int J Pharm Bio Sci. 2017;8(3):250–259.
27. Harrington, R.D.; Hooton, T.M. Urinary tract infection risk factors and gender. J. Gend.- Specif. Med. JGSM Off. J. Partnersh. Women’s Health Columbia 2000, 3, 27–34.
28. Grundy, L.; Caldwell, A.; Brierley, S.M. Mechanisms Underlying Overactive Bladder and Interstitial Cystitis/Painful Bladder Syndrome. Front. Neurosci. 2018, 12, 931.
29. Andolfi, C.; Bloodworth, J.C.; Papachristos, A.; Sweis, R.F. The Urinary Microbiome and Bladder Cancer: Susceptibility and Immune Responsiveness. Bladder Cancer 2020, 6, 225–235.
30. Grigoryan, L.; Mulgirigama, A.; Powell, M.; Schmiemann, G. The emotional impact of urinary tract infections in women: A qualitative analysis. BMC Women’s Health 2022, 22, 182.
31. Barlam, T.F.; Cosgrove, S.E.; Abbo, L.M.; MacDougall, C.; Schuetz, A.N.; Septimus, E.J.; Srinivasan, A.; Dellit, T.H.; Falck-Ytter, Y.T.; Fishman, N.O.; et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2016, 62, e51–e77.
32. Rodriguez-Manas, L. Urinary tract infections in the elderly: A review of disease characteristics and current treatment options. Drugs Context 2020, 9, 1–8.
33. Mancuso, G.; Midiri, A.; Gerace, E.; Biondo, C. Bacterial Antibiotic Resistance: The Most Critical Pathogens. Pathogens 2021, 10, 1310.
34. Perez-Carrasco, V.; Soriano-Lerma, A.; Soriano, M.; Gutierrez-Fernandez, J.; GarciaSalcedo, J.A. Urinary Microbiome: Yin and Yang of the Urinary Tract. Front. Cell. Infect. Microbiol. 2021, 11, 617002.
35. Song, C.H.; Kim, Y.H.; Naskar, M.; Hayes, B.W.; Abraham, M.A.; Noh, J.H.; Suk, G.; Kim, M.J.; Cho, K.S.; Shin, M.; et al. Lactobacillus crispatus Limits Bladder Uropathogenic E. coli Infection by Triggering a Host Type I Interferon Response. Proc. Natl. Acad. Sci. USA 2022, 119, e2117904119.
36. Biehl, L.M.; Farowski, F.; Hilpert, C.; Nowag, A.; Kretzschmar, A.; Jazmati, N.; Tsakmaklis, A.; Wieters, I.; Khodamoradi, Y.; Wisplinghoff, H.; et al. Longitudinal variability in the urinary microbiota of healthy premenopausal women and the relation to neighboring microbial communities: A pilot study. PloS ONE 2022, 17, e0262095.
37. Hudson, R.E.; Job, K.M.; Sayre, C.L.; Krepkova, L.V.; Sherwin, C.M.; Enioutina, E.Y. Examination of Complementary Medicine for Treating Urinary Tract Infections Among Pregnant Women and Children. Front. Pharmacol. 2022, 13, 883216.
38. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022, 399, 629–655.
39. Benito-Villalvilla, C.; Cirauqui, C.; Diez-Rivero, C.M.; Casanovas, M.; Subiza, J.L.; Palomares, O. MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL10 responses via Syk and MyD88. Mucosal Immunol. 2017, 10, 924–
40. Wu, J.; Bao, C.; Reinhardt, R.L.; Abraham, S.N. Local induction of bladder Th1 responses to combat urinary tract infections. Proc. Natl. Acad. Sci. USA 2021, 118, e2026461118.
41. Chegini, Z.; Khoshbayan, A.; Vesal, S.; Moradabadi, A.; Hashemi, A.; Shariati, A. Bacteriophage therapy for inhibition of multi drug-resistant uropathogenic bacteria: A narrative review. Ann. Clin. Microbiol. Antimicrob. 2021, 20, 30.